U.S. markets close in 4 hours 52 minutes
  • S&P 500

    4,236.39
    +11.60 (+0.27%)
     
  • Dow 30

    33,913.27
    +36.30 (+0.11%)
     
  • Nasdaq

    14,171.87
    +30.39 (+0.21%)
     
  • Russell 2000

    2,274.88
    -11.21 (-0.49%)
     
  • Crude Oil

    73.54
    -0.12 (-0.16%)
     
  • Gold

    1,779.80
    -3.10 (-0.17%)
     
  • Silver

    25.86
    -0.16 (-0.61%)
     
  • EUR/USD

    1.1908
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    1.4820
    -0.0020 (-0.13%)
     
  • GBP/USD

    1.3916
    -0.0017 (-0.13%)
     
  • USD/JPY

    110.7270
    +0.4290 (+0.39%)
     
  • BTC-USD

    30,470.77
    -2,363.10 (-7.20%)
     
  • CMC Crypto 200

    726.75
    -67.58 (-8.51%)
     
  • FTSE 100

    7,082.25
    +19.96 (+0.28%)
     
  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference at 11:00 a.m. ET on Tuesday, June 23, 2020. Morphic will give an update on the company’s progress across its portfolio of oral small molecule integrin inhibitors.

A live webcast of the presentation will be available on the Investors section of Morphic’s website at https://www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718